Annual accounts receivable:
$264.93M+$58.48M(+28.33%)Summary
- As of today (August 4, 2025), APLS annual accounts receivable is $264.93 million, with the most recent change of +$58.48 million (+28.33%) on December 31, 2024.
- During the last 3 years, APLS annual accounts receivable has risen by +$254.82 million (+2522.25%).
- APLS annual accounts receivable is now at all-time high.
Performance
APLS Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$214.13M-$21.11M(-8.98%)Summary
- As of today (August 4, 2025), APLS quarterly accounts receivable is $214.13 million, with the most recent change of -$21.11 million (-8.98%) on June 30, 2025.
- Over the past year, APLS quarterly accounts receivable has dropped by -$90.30 million (-29.66%).
- APLS quarterly accounts receivable is now -29.66% below its all-time high of $304.43 million, reached on June 30, 2024.
Performance
APLS Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
APLS Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +28.3% | -29.7% |
| 3 y3 years | +2522.3% | +2748.2% |
| 5 y5 years | - | - |
APLS Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +3328.6% | -29.7% | +2748.2% |
| 5 y | 5-year | at high | >+9999.0% | -29.7% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -29.7% | >+9999.0% |
APLS Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $214.13M(-9.0%) |
| Mar 2025 | - | $235.25M(-11.2%) |
| Dec 2024 | $264.93M(+28.3%) | $264.93M(-5.0%) |
| Sep 2024 | - | $279.01M(-8.4%) |
| Jun 2024 | - | $304.43M(+13.7%) |
| Mar 2024 | - | $267.84M(+29.7%) |
| Dec 2023 | $206.44M | $206.44M(+22.0%) |
| Sep 2023 | - | $169.26M(+52.6%) |
| Jun 2023 | - | $110.91M(+252.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $31.50M(+307.7%) |
| Dec 2022 | $7.73M(-23.5%) | $7.73M(-4.5%) |
| Sep 2022 | - | $8.09M(+7.6%) |
| Jun 2022 | - | $7.52M(+18.8%) |
| Mar 2022 | - | $6.33M(-37.3%) |
| Dec 2021 | $10.10M(>+9900.0%) | $10.10M(+186.9%) |
| Sep 2021 | - | $3.52M(+389.8%) |
| Jun 2021 | - | $719.00K(>+9900.0%) |
| Dec 2020 | $0.00 | $0.00 |
FAQ
- What is Apellis Pharmaceuticals, Inc. annual accounts receivable?
- What is the all time high annual accounts receivable for Apellis Pharmaceuticals, Inc.?
- What is Apellis Pharmaceuticals, Inc. annual accounts receivable year-on-year change?
- What is Apellis Pharmaceuticals, Inc. quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Apellis Pharmaceuticals, Inc.?
- What is Apellis Pharmaceuticals, Inc. quarterly accounts receivable year-on-year change?
What is Apellis Pharmaceuticals, Inc. annual accounts receivable?
The current annual accounts receivable of APLS is $264.93M
What is the all time high annual accounts receivable for Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals, Inc. all-time high annual accounts receivable is $264.93M
What is Apellis Pharmaceuticals, Inc. annual accounts receivable year-on-year change?
Over the past year, APLS annual accounts receivable has changed by +$58.48M (+28.33%)
What is Apellis Pharmaceuticals, Inc. quarterly accounts receivable?
The current quarterly accounts receivable of APLS is $214.13M
What is the all time high quarterly accounts receivable for Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals, Inc. all-time high quarterly accounts receivable is $304.43M
What is Apellis Pharmaceuticals, Inc. quarterly accounts receivable year-on-year change?
Over the past year, APLS quarterly accounts receivable has changed by -$90.30M (-29.66%)